In an open non-comparative trial forty-three hospitalized patients with chronic psoriasis vulgaris were treated with 0.05% halometasone cream (without dressing) by day and 0.05% halometasone ointment (with occlusive dressing) at night. This combined regimen yielded good to very good results in 93.1% of the patients treated. The trial treatment was fairly well tolerated, did not have any systemic adverse effects and had to be discontinued in only one patient, due to severe pustular eruption at the site of application.

Download full-text PDF

Source

Publication Analysis

Top Keywords

halometasone cream
8
halometasone ointment
8
patients chronic
8
chronic psoriasis
8
psoriasis vulgaris
8
005% halometasone
8
halometasone
4
cream day
4
day halometasone
4
ointment night
4

Similar Publications

Introduction: Vitiligo is an immune-related skin disease. Cytokines regulate immune response and inflammation and are involved in the pathogenesis of vitiligo.

Aim: To assess the serum levels of pro-inflammatory cytokines pre- and post- systemic glucocorticoid treatment in patients with active vitiligo.

View Article and Find Full Text PDF

Association of Inflammatory Indicators and Clinical Signs and Itch in Atopic Dermatitis Patients Treated with Simiao Pill Combined with Halomethasone Cream.

J Inflamm Res

August 2023

Department of Dermatology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Second Chinese Medicine Hospital, Nanjing, People's Republic of China.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by symptoms such as itchiness, scaling, and erythema. Previous studies have suggested that inflammatory indicators obtained from peripheral blood cell count can serve as markers for atopic dermatitis pruritus and severity. The objective of this study was to investigate whether these indicators are associated with treatment efficacy in AD patients who received a combination of halomethasone cream and Simiao pill (SMP).

View Article and Find Full Text PDF

Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report.

Ther Adv Chronic Dis

August 2023

Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, No.58 Zhongshan Er Road Guangzhou, Guangdong Province 510080, China.

Alopecia areata (AA) is a chronic inflammatory disease mainly involving Th1 immunoreaction, but Th2 is also involved. A 9-year-old girl presented to our clinic with severe alopecia for 2 months and pruritus-related rashes for 8 years. She was diagnosed with AA and atopic dermatitis (AD), and the Severity of Alopecia Tool (SALT) score was 98.

View Article and Find Full Text PDF

Introduction: The purpose of this study was to assess the efficacy and safety of fractional CO laser combined with halometasone cream in patients with moderate-to-severe chronic hand eczema (CHE).

Methods: A prospective, single-center, parallel-group, open-label randomized trial including 67 patients with moderate-to-severe CHE was carried out. Patients were randomly assigned to group A (n = 33, fractional CO laser once every 4 weeks 1-2 times and halometasone cream twice daily for 8 weeks) or group B (n = 34, halometasone cream alone twice daily for 8 weeks).

View Article and Find Full Text PDF

Objectives: Peripheral blood immune cell profiling of atopic dermatitis patients before and after treatment by single-cell RNA sequencing technique has not been reported. To study the immune Cell Profiling of Atopic Dermatitis Patients Before and After Treatment with Halometasone Cream Wet-Wrap Therapy.

Methods: We used single cell sequencing to detect the proportion change and gene expression change of immune cells in 2 patients before and after treatment, and then used real-time PCR to confirm the mRNA level of differential genes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!